 | ||||||
| "anti diabetes" | ||||||
| NEWS | ||||||
| Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes It improves beta cell function in diabetes models and combines well with current anti-diabetes drugs. Melior expects MLR-1023 will be dosed once ...
| ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.